You are here: Industry Insights > Novartis

News List

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges worldpharmanews
June 29, 2020
Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched.
Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis pharmaceutical-business-review
June 22, 2020
Novartis has secured approval from the US Food and Drug Administration (FDA) for its Cosentyx (secukinumab) to treat active non-radiographic axial spondyloarthritis (nr-axSpA).
Novartis stops HCQ trial against COVID-19 citing participant shortfall expresspharma
June 22, 2020
The move comes in the wake of US FDA’s decision to EUA for hydroxychloroquine and chloroquine against COVID-19.
US FDA approves Novartis’s Ilaris for Active Still’s disease treatment expresspharma
June 18, 2020
Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.
Novartis Announces Update on FDA Review of Ofatumumab americanpharmaceuticalreview
June 15, 2020
Novartis has received notice from the US Food and Drug Administration (FDA) the agency has extended its review of the Supplemental Biologics License Application (sBLA) for ofatumumab (OMB 157) ...
Regulators expand review time for Novartis' MS drug pharmatimes
June 05, 2020
US regulators are extending the review time for Novartis' MS therapy ofatumumab.
Novartis Announces New Ofatumumab Data at EAN americanpharmaceuticalreview
June 03, 2020
Novartis announced new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the 6th Congress of the European Academy of Neurology (EAN).
Novartis’ AveXis agrees to manufacture US researcher Covid-19 vaccine pharmaceutical-technology
June 01, 2020
Novartis unit AveXis has entered a manufacturing agreement with researchers at Massachusetts Eye and Ear and Massachusetts General Hospital in the US to produce a genetic vaccine against Covid-19, AAVCOVID.
Novartis inks deal to make Mass General Brigham’s COVID-19 vaccine candidate expresspharma
May 29, 2020
AveXis, which makes Novartis’s $2.1 million-per-patient gene therapy Zolgensma for the hereditary disease spinal muscular atrophy, is contributing technology, expertise and its manufacturing supply chain at no cost.
New analysis shows survival benefit of Novartis' Kisqali pharmatimes
May 28, 2020
Novartis says a new exploratory subgroup analysis of the Phase III MONALEESA-3 and MONALEESA-7 trials reinforce the overall survival (OS) benefit of Kisqali (ribociclib) in breast cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page